USE OF G CLASS IMMUNOGLOBULINS FOR THE TOPICAL TREATMENT OF ATOPIC DERMATITIS

Abstract: The use of G class immunoglobulins, particularly immunoglobulins for intravenous use (IVIGs) or for intramuscular use (IMIGs), to produce a medicine for the local therapeutic treatment of dermatitis, particularly acne, contact dermatitis, atopic dermatitis, eczema and ichthyosis, psoriasis, papulosquamous dermatopathies (seborrheic dermatitis, erythrodermia, etc.), as well as fungus, parasite, bacterium and virus infection dermatitis and the pharmaceutical composition containing same, are disclosed.

Description: e of G class Immunoglobul ins for the topical treatment of atopic dermatiti s — ooo — The present invention relates to a new therapeutic use of G class immunoglobulins, particularly immunoglobulins for intravenous use (IVTG) or for intramuscular use (IMIG). More particularly, the present invention relates to the topical use of G class immunoglobulins which are normally administered intravenously or intramuscularly for the therapeutic treatment of dermatitis, particularly acne, contact dermatitis, atopic dermatitis, eczema and ichthyosis, psoriasis, papulosquamous dermatopathies (seborrheic dermatitis, erythrodermia, etc.), as well as fungus, parasite, bacterium and virus infection dermatitis. Therefore, this invention also relates to the pharmaceutical compositions suitable for topical application, which contain G class immunoglobulins, and particularly IVTG or IMIG, as the active ingredient. As is well known, the term "immunoglobulins for intravenous use" indicates a human-protein-based product, at least 90% of which has the electrophoretic mobility of gammaglobulin (IgG), at least 90% of IgG being made up of monomer. Traces of IgA and IgM may also be present. The distribution of the IgG subclasses is similar to that encountered in normal serum. Several commercial immunoglobulin preparations for intravenous use are currently available on the market, e.g. under the trade marks VENO- GLOBULIN ® , GAMMIMUNE ® , SANDOGLOBULIN ® , GAMMAGARD ® , GAMMAR ® and IVEGAAM ® . The "immunoglobulins for intramuscular use" differ from the intravenous immunoglobulins in their lower degree of purity. Various commercial preparations of immunoglobulins for intramuscular use are currently available on the market, e.g. under the trade marks GLOBUMAN ® , GAMMABULIN ® , LIOGAMMA ® , BOEHRIGAMMA ® and UMANGAMMA ® . The skin interacts continuously and intimately with a vast range of environmental agents more than any other organ in the body. The environment comes into contact with the body in the form of substances or forces (physical, chemical, biological) and via different routes: irradiation, air, food, direct contact with the skin, injections, or psychosocial interactions. All these agents may lead to diseases of the skin (Ring, J:, "The skin and the environment", Hautarzt. 44:625-35, 1993). Atopic dermatitis (AD) is a multifactorial skin disease with a chronic or chronic-recurrent course, which often sets in during infancy. The aetiology of this troublesome skin condition is still obscure, but an immunological disorder of the T cell immune response is likely involved in its pathogenesis (Wuthrich, B., Atopic dermatitis", Ther. Umsch.. 51:45-54, 1994). Recent discoveries have revealed various key factors in maintaining the vicious circle of AD, associated with elevated activation of T lymphocytes, hyper- stimulating Langerhans cells, an abnormal cell-mediated immunity and an overproduction of IgEs by the B cells (Cooper, K.D., "Atopic dermatitis: recent trends in pathogenesis and therapy", J. Invest. Dermatol.. 102:128-37, 1994). In-situ hybridization has revealed that, as compared to normal control skin or to the unaffected skin of AD sufferers, the acute and chronic lesions of the skin had a significantly greater numbers of cells which were positive for IL-4 and IL-5 mRNA (Hamid, Q., et al. "Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis", J. Clin. Invest.. 94:870-6, 1994). These and other data suggest the activation of a selected population of T-helper cells which produce a type of Th2 cytokines related to IL-4 and IL-5 but not to IL-2 and interferon-γ (IFN-γ) in AD (Kagi, M.K., et al, "Differential cytokine profiles in peripheral blood lymphocyte supernatants and skin biopsies from patients with different forms of atopic dermatitis, psoriasis and normal individuals", Int. Arch. Allergy Immunol.. 103:332-40, 1994). The micro-organisms of the skin flora may also be a further stimulus for allergic reactions of the skin. Abnormal bacterial colonization of the skin is a typical characteristic of AD. Staphylococcus aureus (Staph. aureus) is the most common pathogen and in some cases an antimicrobial and antifungal treatment has proved useful (Ring, J., et al, " Atopic eczema: role of micro-organisms on the skin surface", Allergy. 47:265- 9, 1992). Conventional therapy remains the mainstay of treatment of atopic dermatitis, but often proves unsatisfactory. New therapies based on the concepts outlined above are being tested in clinical trials, and for this purpose trials have been suggested with modifiers of the biological response such as interferon-γ, cyclosporin A, or thymopentin, administered parenterally (Cooper, K.D., "Atopic dermatitis: recent trends in pathogenesis and therapy". J. Invest. Dermatol.. 102:128-37, 1994). To date, the accepted use of IVIG and IMIG has been as antibody replacement in states of immunodeficiency to treat and/or prevent infectious d seases (Newland A.C., "The use and mechanism of action of intravenous immunoglobulin", Br. J. Haemato . 72:301-5, 1989). In addition, there is increasing evidence that intravenous infusion of large amounts of polymeric immunoglobulin causes more than simple antibody replacement and may have a profound effect on the reticulendothelial system. IVIG and IMIG can alter the function of B and T lymphocytes and cause short-term blockade of phagocyte function with down-regulation of immunological activity (Newland, A.C., Macey et al, "Intravenous immunoglobulin: mechanism of action and their clinical application" in "Immunotherapy with intravenous immunoglobulins", edited by P. Imbrach, Academic Press, London, 1991, pp. 14-25). It is conceptually important to note that, in numerous diseases, more than one mechanism of action is possible and that the therapeutic effect may be due to several concomitant actions rather than to any single mechanism. Nevertheless, the IVTG and IMIG preparations have been developed to date so as to allow systemic administration. As regards skin diseases, an improvement in AD has been observed in patients suffering both from AD and from Kawasaki's disease or from idiopathic thrombocytopenia, but the immunoglobulins were administered, as usual, by the intravenous route and at high doses (Kimata, H., "High dose gammaglobulin treatment for atopic dermatitis", Arch. Pis. Child.. 70:335-6, 1994). Surprisingly, however, it has now been found that G class immunoglobulins, and in particular IVIGs or IMIGs, in solution or in the form of ointments or gels, or in liposomes (or other formulations) at concentrations of 0.1-25% are potentially effective for the prophylaxis and treatment of AD or of other skin diseases characterized by a poorly regulated immune response and/or by abnormal bacterial, viral or fungal colonization. 4 This efficacy of the immunoglobulins has been tested in various studies in man. Some of these studies will now be described here. The local administration of immunoglobuUns at the doses indicated brings about remission of the inflammatory process without causing any toxic or unwanted side effects. Studies in man Study No. 1 In this study we selected 8 patients suffering from acute AD in whom we studied blood levels of total lymphocytes as well as of CD3, CD4 and CD 8, and the CD4:CD8 ratio. These parameters were determined in two clinical phases, i.e. in the acute phase (pre-treatment) and in another phase in which the lesions regressed (post-treatment). IVIGs were administered topically in the form of a 25% solution. The IVIGs were applied to the skin lesions three times daily for a period of 14 days. The aim of this work was to study the changes in these lymphocyte subpopulations in each of the phases. We also studied a control group consisting of 8 healthy subjects so as to reinforce the results obtained. We found no significant difference between the results obtained in the two phases or as compared to the control group (Table 1). These data indicate that IVIGs when applied topically in the form of a 25% solution, do not modify the lymphocyte subpopulations in peripheral blood. Their therapeutic efficacy is thus attributable to a local effect. Table 1 Absolute number of lymphocytes in peripheral blood: percentages of CD3. CD4 and CD8 cells and CD4:CD8 ratio. Lymphocytes CD3 CD4 CD8 CD4:CD8 Statistics Patients Before 1870±324 67±13 41±8 27±0 1.6 ns After 19201376 72±15 88±6 16±7 1.4 ns Controls Before 19031411 70112 49110 2919 1.4 ns After 19281407 7018 40111 2818 1.4 ns Study No. 2 In this study IVIGs were administered topically in the form of a 0,1% solution and applied to the skin lesions three times daily for a period of 14 days. A total of 6 patients with acute AD lesions were treated. No other type of treatment was allowed. We used in situ hybridization, as previously described (Hamid, Q., et al "Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis", J. Clin. Invest:. 94:870-6, 1994) to examine the expression of the messenger RNA (mRNA) of interleukin 4 (IL-4) and interleukin 5 (IL-5) in skin biopsies. In comparison with pre-treatment the skin lesions were no longer present and a significantly lower number of cells positive for IL-4 (P < 0.01) and IL-5 (P < 0.01) mRNA were detected (Table 2). These data indicate that acute AD lesions are associated with an increased activation of the IL-4 and IL-5 genes, and that treatment with IVIGs is followed by a reduced expression of IL-4 and IL-5 at local level. Table 2 Differential in situ cvtokine gene expression in skin biopsies before and after treatment. Results are expressed as mean number of positive cells per high notencv field rθ.202 mm 2 ) Pre-treatment Post- treatment Statistics IL-4 mRNA 22+4 412 P<0.01 IL-5 mRNA 1415 211 P<0.01 Studv No. 3 In this study we assessed the expression of Thl-like cytokine and interferon-γ in three patients suffering from AD in whom a Staph. aureus superinfection had been observed clinically and confirmed microbiologically by skin biopsy culture. In comparison with normal skin (3 volunteers), the expression of interferon-γ increased in the AD lesions. After treatment with IVIG in the form of a 5% suspension 4 times daily for 16 days, the lesions disappeared and the increased expression of interferon-γ mRNA proved to be significantly down controlled (Table 3). These data indicate that the thera-peutic efficacy of IVIGs is associated with a reduced colonization by micro-organisms and with modulation of interferon-γ mRNA expression. Table 3 Differential in situ interferon-v gene expression in skin biopsies before and after treatment in patients and controls. Results are expressed as mean number of positive cells per high potency field (0.202 mm- ? ) Pre-treatment Post-treatment Statistics Patients 30+6 14±5 P< 0.02 Control 7±3 815 ns The compositions of the invention (solutions, ointments, creams gels, liposomes, etc.) can be prepared using conventional techniques and excipients, e.g. as described in "Remington's Pharmaceutical Sciences Handbook", Mack Pub. Co., New York, USA, XVIII Ed., 1984, as will be self- evident to any person skilled in the art. In addition to suitable excipients, these compositions may also contain antibiotics, antiviral agents, antifungal agents, vitamins, anti -inflammatory agents, antipruritics and or antimicrobials, unsaturated fatty acids and immunosuppressive agents.

Claims: Claims 1. Use of G class immunoglobulins to produce a medicine for the local therapeutic treatment of dermatitis. 2. The use of Claim 1 wherein dermatitis is acne, contact dermatitis, atopic dermatitis, eczema and ichthyosis, psoriasis, papulosquamous derma¬ topathies (seborrheic dermatitis, and erythrodermia) as well as fungus, parasite, bacterium and virus infection dermatitis. 3. The use of Claim 1 or 2 to produce solutions, ointments, creams, gels and liposomes. 4. The use of any of the preceding Claims wherein the immunoglobulins are combined with antibiotics, antiviral agents, antifungal agents, vitamins, anti-inflammatory agents, antipruritics and/or antimicrobials, unsaturated fatty acids and immunosuppressive agents. 5. The use of any of the preceding Claims wherein the immunoglobulins are immunoglobulins for intravenous use (IVIGs). 6. The use of any of Claims 1 to 4 wherein the immunoglobulins are immunoglobulins for intramuscular use (IMIGs). 7. A pharmaceutical composition suitable for the topical application for the treatment of dermatitis, comprising an amount of G class immuno¬ globulins as the active ingredient suitable for inducing remission of the inflammatory process in a patient suffering from dermatitis, and at least one pharmacologically acceptable excipient. 8. The composition of Claim 7 wherein dermatitis is acne, contact dermatitis, atopic dermatitis, eczema and ichthyosis, psoriasis, papulosquamous dermatopathies (seborrheic dermatitis, and erythrodermia) as well as fungus, parasite, bacterium and virus infection dermatitis. 9. The composition of Claim 7 or 8 in the form of a solution, ointment, cream, gel or liposome. 10. The composition of Claim 9 comprising from 0.1 to 25% of G class immunoglobulins . 11. The composition of any of Claims 7 to 10 which also comprises antibiotics, antiviral agents, antifungal agents, vitamins, anti-inflammatory agents, antipruritics and/or antimicrobials, unsaturated fatty acids and immunosuppressive agents. 12. The composition of any of Claims 7 to 11 wherein the G class immunoglobulins are immunoglobulins for intravenous use (IVIGs). 13. The composition of any of Claims 7 to 11 wherein the G class immunoglobuUns are immunoglobulins for intramuscular use (IMIGs).

Inventors: BRUSCHI PIETRO, DE SIMONE CLAUDIO, BRUSCHI, PIETRO, DE SIMONE, CLAUDIO
Applicants: BRUSCHI PIETRO, MENDES SRL, SIMONE CLAUDIO DE, BRUSCHI, PIETRO, DE SIMONE, CLAUDIO, MENDES S.R.L.
Application year: 1996
Main classification: A61K39
IPC codes: A61K9, A61K38, A61K39, A61K45, A61P17, A61P29, A61P43, C07K16